The Alzheimer’s Association is the leading voluntary health organization in Alzheimer care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. About us.
Neelum T Aggarwal, M.D.
An Associate Professor in the Department of Neurological Sciences at Rush University Medical Center in Chicago and a steering committee member at Alzheimer’s Disease Cooperative Study Group, Dr. Aggarwal, is a cognitive neurologist with particular interest in all types of dementia (Alzheimer’s disease, fronto temporal dementia, vascular dementia and Lewy body dementia). In addition to her active clinical practice, she continues to conduct original research in a variety of large scale community-based studies. She is the co-investigator on multiple grants funded by the National Institute on Aging (NIA). In addition, she is a speaker to many community and business organizations that seek to gain a better understanding of the changes—cognitively and physically—in the aging process, and is an advisor for community-based and minority health initiatives.
Paul Aisen, M.D., is a professor of neurology and the founding director of USC Alzheimer’s Therapeutic Research Institute (ATRI). Dr. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. With his expertise and leadership, Keck School of Medicine of USC will create a leading hub of basic, translational and clinical research in neuroscience and neurological diseases. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multi-center therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study. Aisen has collaborated extensively with the biotech and pharmaceutical industries for many years. He has led numerous multicenter trials, and has authored more than 350 scientific papers.
Robert Egge is the Alzheimer’s Association’s Chief Public Policy Officer, and Executive Director of the Alzheimer’s Impact Movement. Mr. Egge leads the Association’s efforts to elevate Alzheimer’s as a critical federal and state government priority and to implement policies to better serve those affected by Alzheimer’s disease and other dementia. Chief among these priorities are increasing federal funding for Alzheimer’s research and implementing more effective care and support services at the federal and state levels.
Harry Johns has served as the president and chief executive officer of the Alzheimer’s Association since 2005. Since his arrival, the Alzheimer’s Association has built new momentum for its vision of a world without Alzheimer’s, including the first nationwide campaign to increase understanding and awareness about Alzheimer’s disease, an emphasis on accelerated treatment progress through the promotion of participation in clinical studies, a campaign to enhance early detection of the disease, tools designed to support both individuals with the disease and their caregivers, and targeted research funding to advance diagnosis and treatment. Harry was appointed by the Secretary of Health and Human Services in 2011 to serve as a member of the Advisory Council on Alzheimer’s Research, Care, and Services. He also serves as CEO of the Alzheimer’s Impact Movement and on the Executive Committee of Research!America. Prior to joining the Alzheimer’s Association, he was one of the four members of the executive team of the American Cancer Society.
Michael Rafii, M.D., Ph.D., is Associate Professor of Clinical Neurology at the Keck School of Medicine of the University of Southern California (USC) and Clinical Director of the Alzheimer’s Therapeutic Research Institute (ATRI). He received his MD and PhD degrees from Brown University School of Medicine and conducted neurogenetics research at Harvard Medical School. He holds two patents for protein-based therapeutics resulting from his work while a graduate student. Dr. Rafii completed his residency in Neurology at the Johns Hopkins Hospital, where he was chief resident. He then undertook a fellowship in dementia and cognitive disorders at UC San Diego. Dr. Rafii’s research focuses on the design and conduct of clinical trials for Alzheimer’s disease including Alzheimer’s disease in people with Down syndrome. He has led both phase I and phase II multi-center clinical trials. Dr. Rafii also serves on the National Task Group on Intellectual Disabilities and Dementia Practices of the American Academy of Developmental Medicine. He is ad hoc member of the NIH study section on Developmental Brain Disorders and co-editor of the textbook ‘Common Pathogenic Mechanisms between Down Syndrome and Alzheimer’s Disease: Steps toward Therapy.’ He previously served as Medical Director of the Alzheimer’s Disease Cooperative Study (ADCS), Director of the UC San Diego Memory Disorders Clinic and Director of the Neurology Residency Training program at UC San Diego.
Sherri Snelling, CEO and founder of the Caregiving Club, is a nationally recognized expert on America’s 65 million family caregivers with special emphasis on how to help caregivers balance “self care” while caring for a loved one. She is the former chairman of the National Alliance for Caregiving and is currently writing a book about celebrities who have been caregivers. She also has served on the caregiving advisory councils for the Centers for Medicare and Medicaid Services (CMS) as well as the Centers for Disease Control (CDC).